In this episode, Hall welcomes Robert Davidson, CEO of CURE Pharmaceutical.
CURE Pharmaceutical is an innovative drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry-leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel, and Germany, among other markets.
Prior to his role at CURE Pharmaceutical, Robert served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Robert was responsible for the development of several drug delivery technologies and commercial brand extensions including the popular zinc product Zicam. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. He received his B.S. degree with a concentration in Biological Life Sciences and has a Masters Certificate in Applied Project Management from Villanova University, a Masters of Public Health from American Military University, Virginia, and a Masters in Health and Wellness from Liberty University, Virginia. Robert also completed his Post Graduate Studies at the University of Cambridge.
Robert discusses the growth rate of the sector, the future of drug delivery, and some of the challenges he has faced.
Robert can be contacted via LinkedIn at www.linkedin.com/in/rob-davidson-a6baa06/.
For a full transcript, click here.
Music courtesy of Bensound.
Copyright (c) 2023, Hall Martin and investorconnect.org. All rights reserved.
Hall T Martin is the director of Investor Connect, which is a 501(c)(3) nonprofit dedicated to the education of investors for early-stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon for the basis of investment decisions.